- Home
- PAYO vs PTGX Comparison
PAYO vs PTGX Comparison
Compare PAYO & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYO
- PTGX
- Stock Information
- Founded
- PAYO 2005
- PTGX 2006
- Country
- PAYO United States
- PTGX United States
- Employees
- PAYO N/A
- PTGX N/A
- Industry
- PAYO EDP Services
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- PAYO Technology
- PTGX Health Care
- Exchange
- PAYO Nasdaq
- PTGX Nasdaq
- Market Cap
- PAYO 2.5B
- PTGX 3.3B
- IPO Year
- PAYO N/A
- PTGX 2016
- Fundamental
- Price
- PAYO $6.98
- PTGX $51.05
- Analyst Decision
- PAYO Strong Buy
- PTGX Strong Buy
- Analyst Count
- PAYO 8
- PTGX 9
- Target Price
- PAYO $10.44
- PTGX $67.11
- AVG Volume (30 Days)
- PAYO 2.6M
- PTGX 1.0M
- Earning Date
- PAYO 08-06-2025
- PTGX 08-05-2025
- Dividend Yield
- PAYO N/A
- PTGX N/A
- EPS Growth
- PAYO N/A
- PTGX N/A
- EPS
- PAYO 0.28
- PTGX 0.86
- Revenue
- PAYO $996,150,000.00
- PTGX $207,801,000.00
- Revenue This Year
- PAYO $4.32
- PTGX N/A
- Revenue Next Year
- PAYO $5.59
- PTGX $47.15
- P/E Ratio
- PAYO $24.89
- PTGX $59.19
- Revenue Growth
- PAYO 14.86
- PTGX N/A
- 52 Week Low
- PAYO $5.03
- PTGX $32.50
- 52 Week High
- PAYO $11.29
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- PAYO 55.09
- PTGX 45.80
- Support Level
- PAYO $6.61
- PTGX $49.86
- Resistance Level
- PAYO $6.95
- PTGX $57.24
- Average True Range (ATR)
- PAYO 0.19
- PTGX 2.06
- MACD
- PAYO 0.04
- PTGX -0.78
- Stochastic Oscillator
- PAYO 82.96
- PTGX 16.14
About PAYO Payoneer Global Inc.
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.